See What HealthDay Can Do For You
Contact Us

Von Willebrand Factor Linked to Bleeding Complications

Bleeding, mortality up in oral anticoagulation-treated patients with high levels of VWF

Von Willebrand Factor Linked to Bleeding Complications

FRIDAY, March 9 (HealthDay News) -- Oral anticoagulation (OAC)-treated patients with high levels of von Willebrand factor (VWF) have elevated risks of bleeding complications and cardiovascular and all-cause mortality, according to a study published in the March issue of the Journal of Internal Medicine.

Marcus Lind, M.D., of Umeå University Hospital in Sweden, and associates conducted a longitudinal study of 719 patients receiving OAC treatment to evaluate the link between VWF plasma levels and risk of bleeding complications, cardiovascular death, and all-cause mortality.

During 4.2 years of follow-up, the researchers identified 113 cases of clinically relevant bleeding and 73 cases of major bleeding; and there were 161 deaths, including 110 attributed to cardiovascular disease. There was a significantly increased risk of bleeding complications for patients in the highest tertile of VWF (hazard ratio [HR] for major bleeding, 2.53; HR for clinically relevant bleeding, 2.19). VWF was significantly associated with cardiovascular and all-cause mortality (HR, 1.68 and 1.77, respectively). These findings were significant after adjusting for age, high-sensitivity C-reactive protein, and creatinine.

"Our findings imply that the use of VWF as a risk marker for thromboembolic events is complicated by the association of VWF with bleeding complications," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.